Journal of Peking University (Health Sciences) ›› 2026, Vol. 58 ›› Issue (1): 201-207. doi: 10.19723/j.issn.1671-167X.2026.01.027

Previous Articles     Next Articles

Clinical features and virulence gene distribution of Klebsiella pneumoniae multi-site infection in patients with hospital-acquired pneumonia

Yunling GENG, Chao LIU, Ping YANG, Jiajia ZHENG, Ning SHEN, Yipeng DU*()   

  1. Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China
  • Received:2024-05-03 Online:2026-02-18 Published:2025-01-26
  • Contact: Yipeng DU
  • Supported by:
    National Key Research and Development Program(2022YFC2303200); Key Research and Development Project of Peking University Third Hospital(BYSYZD2022007)

RICH HTML

  

Abstract:

Objective: To analyze the clinical features and virulence gene characteristics of Klebsiella pneumoniae multi-site infections in patients with hospital-acquired pneumonia, as well as the risk factors for death within 30 days in patients with multi-site infections, in order to provide help for clinical anti-infective treatment. Methods: The case data of hospital-acquired pneumonia patients with Klebsiella pneumoniae isolated in sputum culture from March 2018 to June 2023 in Peking University Third Hospital were selected for retrospective analysis, and a total of 128 consecutive patients were enrolled, of whom 35 were in the multi-site infection group and 93 were in the lung infection group, and the clinical data, strain sequence typing, and virulence-related genes of the patients in the two groups were analyzed and compared. Results: The differences in age, gender, proportion of the patients with length of hospital stay ≥30 days, antibiotic exposure rate within 90 days and 30-day mortality rate between the two groups were statistically significant (all P < 0.05); the differences in the proportions of combined interstitial lung disease, myocardial infarction, peripheral vascular disease, peptic ulcer, diabetes mellitus and hemiplegia between the two groups were statistically significant (all P < 0.05). The proportions of patients with Glasgow coma scale (GCS) scores < 8 points, the proportion of the patients who underwent peripherally inserted central catheter (PICC) and gastric tube invasive operation, the proportion of the presence of pleural effusion and infectious shock in the multi-site infection group were significantly higher than those of the pulmonary infection group (all P < 0.05). The blood procalcitonin (PCT) level in the multi-site infection group was significantly higher than that of the pulmonary infection group (P=0.004), and the red blood cell count and hemoglobin level were significantly lower than those of the pulmonary infection group (P < 0.001). The proportion of ST11 and the detection rates of virulence genes iroB, ybtA, irp1 and fyuA in Klebsiella pneumoniae strains in the multi-site infection group were significantly higher than those in the pulmonary infection group (P < 0.05). According to the occurrence of death within 30 days, the patients in the multi-site infection group were further divided into the multi-site infection survival group (n=21) and the non-survival group (n=14). Multivariate analysis showed that septic shock was an independent risk factor for death within 30 days of multi-site infection (P=0.045, OR=38.510). Conclusion: Patients with Klebsiella pneumoniae multi-site infection were mainly found in patients with advanced age, female, more comorbidities, performing invasive operation and having history of antimicrobial drug exposure within 90 days. They had lower erythrocyte counts, hemoglobin levels and higher PCT levels, and were prone to pleural effusion, infectious shock. Infectious shock was an independent risk factor for death within 30 days in patients with Klebsiella pneumoniae multi-site infection. ST11 type was the most prevalent type of multi-site infectious strains, and the virulence genes iroB, ybtA, irp1, fyuA were more prevalent.

Key words: Hospital-acquired pneumonia, Klebsiella pneumoniae, Virulence, Bacterial genes, Multi-site infection

CLC Number: 

  • R563.11

Table 1

Comparison of general information between the multi-site infection group and lung infection group"

Items Multi-site infection group (n=35) Lung infection group (n=93) Z/χ2 P
Age/years 85 (82, 88) 79 (69, 85) 2.513 0.012
Sex (male/female) 15/20 67/26 9.409 0.002
Length of hospitalization ≥30 d 29 (82.9) 35 (37.6) 20.802 < 0.001
Admission to intensive care unit 24 (68.6) 59 (63.4) 0.221 0.638
History of antimicrobial exposure within 90 d 34 (97.1) 75 (80.6) 5.476 0.019
30-day mortality 14 (40.0) 14 (15.1) 9.260 0.002
Distribution of specimens
    Sputum and pulmonary alveolar lavage fluid 35 (100.0) 93 (100.0)
    Urine 19 (54.3) 0 (0)
    Blood 13 (37.1) 0 (0)
    Surgical wound discharge 2 (5.7) 0 (0)
    Ascites 1 (2.9) 0 (0)
Distribution of departments
    Intensive care unit 20 (57.1) 36 (38.7) 3.511 0.061
    Emergency department ward 7 (20.0) 7 (7.5) 2.882 0.090
    Respiratory medicine department 1 (2.9) 16 (17.2) 3.385 0.066
    Other internal medicine wards 6 (17.1) 21 (22.6) 0.452 0.501
    Other surgical wards 1 (2.9) 13 (14.0) 2.188 0.139

Table 2

Drug resistance of the multi-site infection group and lung infection group"

Items Multi-site infection group (n=35) Lung infection group (n=93) P
Amoxicillin / Clavulanate 22 (73.3) 34 (47.2) 0.016
Piperacillin / Tazobactam 27 (79.4) 37 (42.0) < 0.001
Cefatriaxone 27 (79.4) 43 (49.4) 0.003
Cefepime 28 (80.0) 42 (45.7) 0.001
Ceftazidime 28 (80.0) 42 (45.7) 0.001
Ceftazidime / Avibactam 13 (37.1) 1 (1.8) < 0.001
Cefoperazone / Sulbactam 25 (71.4) 39 (41.9) 0.003
Levofloxacin 28 (80.0) 42 (45.7) 0.001
Ciprofloxacin 28 (82.4) 44 (51.2) 0.002
Minocycline 14 (40.0) 23 (25.0) 0.096
Doxycycline 10 (37.0) 19 (29.2) 0.463
Tigecycline 0 (0) 0 (0)
Meropenem 22 (62.8) 33 (36.3) 0.007
Imipenem 22 (62.8) 34 (37.0) 0.009
Ertapenem 20 (57.1) 35 (38.5) 0.058
Amikacin 18 (51.4) 22 (23.9) 0.003
Aztreonam 19 (73.1) 30 (43.5) 0.010
Cotrimoxazole 12 (34.2) 30 (32.6) 0.858
Colistin 4 (16.0) 1 (1.6) 0.024
Tobramycin 14 (53.8) 18 (26.5) 0.012

Table 3

Comparison of comorbidities, disease severity score, invasive procedures, and complications between the multi-site infection group and lung infection group"

Items Multi-site infection group (n=35) Lung infection group (n=93) χ2 P
Comorbidities
    Interstitial lung disease 5 (14.3) 3 (3.2) 5.309 0.021
    Myocardial infarction 9 (25.7) 6 (6.5) 9.121 0.003
    Peripheral vascular disease 19 (54.3) 14 (15.1) 20.455 < 0.001
    Peptic ulcer 17 (48.6) 1 (1.1) 47.469 < 0.001
    Diabetes mellitus 1 (2.9) 33 (35.5) 13.877 < 0.001
    Hemiplegia 13 (37.1) 1 (1.1) 33.960 < 0.001
Disease severity score
    CCI score>4 8 (22.9) 9 (9.7) 3.835 0.076
    GCS score < 8 15 (42.9) 16 (17.2) 9.118 0.003
Invasive procedures
    CVC 18 (51.4) 40 (43.0) 0.727 0.394
    PICC 15 (42.9) 11 (11.8) 15.126 < 0.001
    Catheter 29 (82.9) 6 (17.1) 0.175 0.676
    Tracheal intubation 13 (37.1) 29 (31.2) 0.410 0.522
    Gastric tube 32 (91.4) 62 (66.7) 7.993 0.005
    Drainage tube 7 (20.0) 17 (18.3) 0.049 0.824
Complications
    Pleural effusion 21 (60.0) 36 (38.7) 4.667 0.031
    Infectious shock 13 (37.1) 8 (8.6) 15.104 < 0.001
    Respiratory failure 14 (40.0) 39 (41.9) 0.039 0.843

Table 4

Comparison of the laboratory test results between the the multi-site infection group and lung infection group"

Items Multi-site infection group (n=35) Lung infection group (n=93) t/Z P
WBC/(×109/L) 8.94 (6.88, 12.13) 9.44 (6.28, 14.25) 1.251 0.211
RBC/(×1012/L) 2.94±0.68 3.64±0.82 4.595 < 0.001
HB/(g/L) 89.17±19.91 110.74±25.50 4.799 < 0.001
HCT 0.28±0.07 0.34±0.08 0.438 0.662
PLT/(×109/L) 195.17±114.03 207.91±96.68 1.842 0.068
NEUT/% 80.65 (69.25, 87.75) 78.45 (70.73, 83.80) 1.756 0.079
NEUT/(×109/L) 6.36 (4.81, 10.30) 7.51 (4.39, 12.11) 1.016 0.310
TB/(μmol/L) 13.25 (10.10, 17.03) 12.70 (8.93, 24.63) 0.380 0.704
Cr/(μmol/L) 69.00 (37.00, 179.50) 72.50 (48.50, 98.50) 0.527 0.598
ALB/(g/L) 32.70 (29.35, 36.25) 32.15 (28.36, 35.45) 0.782 0.434
ALT/(U/L) 19.00 (13.00, 36.75) 22.50 (12.75, 42.50) 0.354 0.724
AST/(U/L) 29.00 (22.00, 37.75) 26.00 (19.00, 43.00) 1.261 0.207
ALP/(U/L) 117.00 (76.25, 141.25) 89.50 (71.75, 128.25) 1.450 0.147
PCT/(μg/L) 0.27 (0.13, 2.61) 0.11 (0.05, 0.50) 2.887 0.004
PT/s 12.90 (11.18, 14.85) 12.40 (11.48, 14.23) 0.830 0.407
INR 1.21 (1.04, 1.38) 1.15 (1.07, 1.32) 0.788 0.431
D-dimer/(mg/L) 0.71 (0.42, 1.23) 0.68 (0.28, 1.49) 1.677 0.094
HbA1C/% 6.07±0.75 6.34±0.72 0.312 0.756
FBG/(mmol/L) 5.79 (5.23, 7.54) 6.10 (5.60, 7.20) 0.538 0.591

Table 5

Comparison of sequence typing and virulence genes between the multi-site infection group and lung infection group"

Items Multi-site infection group (n=35) Lung infection group (n=93) χ2 P
Sequence typing 6.616 0.01
    ST11 20 (57.1) 30 (32.3)
    Non-ST11 15 (42.9) 63 (67.7)
Virulence genes
    iucA 19 (54.3) 40 (43.0) 1.301 0.254
    iroB 6 (17.1) 36 (38.7) 5.365 0.021
    rmpA 9 (25.7) 38 (40.9) 2.511 0.113
    rmpA2 16 (45.7) 36 (38.7) 0.517 0.472
    peg-344 9 (25.7) 39 (41.9) 2.855 0.091
    ybtA 30 (85.7) 61 (65.6) 5.011 0.025
    irp1 30 (85.7) 61 (65.6) 5.011 0.025
    fyuA 30 (85.7) 61 (65.6) 5.011 0.025
String test 12 (34.3) 28 (30.1) 0.207 0.649
hvKP 22 (62.9) 62 (66.7) 0.164 0.686

Table 6

Multivariate analysis of survivors and deaths in the multi-site infection group"

Items B Standard error of B Wald χ2 P OR
RBC 6.229 4.929 1.597 0.206 507.157
HB -0.316 0.209 2.271 0.132 0.729
PLT -0.013 0.009 1.905 0.168 0.987
D-dimer 0.400 0.358 1.245 0.265 1.492
Infectious shock 3.651 1.819 4.027 0.045 38.510
hvKP -0.147 1.312 0.013 0.911 0.863
1
Wyres KL , Lam MMC , Holt KE . Population genomics of Klebsiella pneumoniae[J]. Nat Rev Microbiol, 2020, 18 (6): 344- 359.

doi: 10.1038/s41579-019-0315-1
2
陈彦欣, 徐燕萍, 朱迎钢, 等. 耐多黏菌素肺炎克雷伯菌的诊治进展[J]. 中华结核和呼吸杂志, 2023, 46 (8): 813- 818.
3
李星宇, 申川, 王亚东, 等. 高毒力肺炎克雷伯菌肝脓肿的诊治进展[J]. 中华传染病杂志, 2021, 39 (2): 116- 120.
4
Matono T , Morita M , Nakao N , et al. Genomic insights into virulence factors affecting tissue-invasive Klebsiella pneumoniae infection[J]. Ann Clin Microbiol Antimicrob, 2022, 21 (1): 2.

doi: 10.1186/s12941-022-00494-7
5
Liu KL , Sun HY , Fang CT . Liver abscess and metastatic endophthalmitis secondary to Klebsiella pneumoniae K1[J]. Am J Gastroenterol, 2017, 112 (1): 13.
6
Yoon JH , Kim YJ , Jun YH , et al. Liver abscess due to Klebsiella pneumoniae: Risk factors for metastatic infection[J]. Scand J Infect Dis, 2014, 46 (1): 21- 26.

doi: 10.3109/00365548.2013.851414
7
Kim SJ , Chu ST , Lee KS , et al. Metastatic endophthalmitis and thyroid abscess complicating Klebsiella pneumoniae liver abscess[J]. Clin Mol Hepatol, 2018, 24 (1): 88- 91.

doi: 10.3350/cmh.2016.0066
8
中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41 (4): 255- 280.
9
Wu H , Li D , Zhou H , et al. Bacteremia and other body site infection caused by hypervirulent and classic Klebsiella pneumoniae[J]. Microb Pathog, 2017, 104, 254- 262.

doi: 10.1016/j.micpath.2017.01.049
10
麦东媚, 钟嘉城, 谭俊青. 1 852株肺炎克雷伯菌的临床分布和耐药及感染影响因素研究[J]. 国际医药卫生导报, 2023, 29 (15): 2110- 2116.
11
刘秀凤, 肖志军, 唐群力, 等. 老年住院患者感染肺炎克雷伯菌的临床特点及耐药性分析[J]. 老年医学与保健, 2023, 29 (1): 43- 48.
12
Lee SS , Chen YS , Tsai HC , et al. Predictors of septic metastatic infection and mortality among patients with Klebsiella pneumoniae liver abscess[J]. Clin Infect Dis, 2008, 47 (5): 642- 650.

doi: 10.1086/590932
13
Lin JC , Siu LK , Fung CP , et al. Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control[J]. J Clin Endocrinol Metab, 2006, 91 (8): 3084- 3087.

doi: 10.1210/jc.2005-2749
14
马海艳, 刘学文, 马文东, 等. 老年患者CRKP与CSKP感染临床特点以及毒力相关基因分布差异[J]. 传染病信息, 2023, 36 (4): 325- 330.
No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!